NEU Neuren set for FDA talks on trial to treat developmental genetic disorders Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial. Caroline Smith 1 day ago ASX News Healthcare Biotechnology
1AD 'East to West': AdAlta unveils new strategy to find drug candidates, but appears to've ditched AD-214 AdAlta plans to take cell therapy candidates from Southeast Asia, firm them in Aus tests, and then licence products to Europe and America. Jonathon Davidson 2 days ago ASX News Healthcare Biotechnology
CYP Cynata's stem cell tech verified in peer-reviewed study Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal. Jonathon Davidson 3 days ago ASX News Healthcare Biotechnology
NUZ Neurizon snags US patent for NUZ-001 after winning FDA orphan status in 2024 Neurizon (ASX:NUZ) has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, designated orphan status by the FDA last year. The microcap stock jumped +12% to 14cps in early trades, per Cboe live pricing data. The State-side move ultimately firms up ... Jonathon Davidson 3 days ago ASX News Healthcare Biotechnology
PME Imaging giant Pro Medicus notches all time high on $50M+ deal Pro Medicus (ASX:PME) has notched a new all time high climbing over $280.50/sh on the back of a 7 year deal worth $53M with US player BayCare. Jonathon Davidson 4 days ago ASX News Healthcare Medical Devices
WNX Wellnex jumps as TGA ticks off on liquid paracetamol, caffeine combination Wellnex Life (ASX:WNX) jumped 6% to 70cps heading into lunchtime trades Sydney time as the TGA greenlights its liquid paracetamol and caffeine combination. Jonathon Davidson 4 days ago ASX News Healthcare Cannabis
AGN Argenica rat brain study shows potential neuroprotective action in ARG-007 Argenica Therapeutics's rat study of its traumatic brain injury drug ARG-007 has shown early-stage evidence of neuroprotective action. Jonathon Davidson 4 days ago ASX News Healthcare Biotechnology
NOX Noxopharm jumps as flagship lupus drug clears first-pass in vitro safety tests Noxopharm has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials. Jonathon Davidson 4 days ago ASX News Healthcare Biotechnology
FPH Fisher & Paykel point to raised costs in FY26 on back of Trump tariffs Fisher and Paykel (ASX:FPH) has revealed that it expects Trump's tariffs against Mexico to raise its costs in FY26 with a full outlook report to be calculated. Jonathon Davidson 5 days ago ASX News Healthcare Medical Devices
OIL Optiscan starts German trial to test imaging capability on gastrointestinal tract Optiscan Imaging Ltd has begun a pre-clinical trial in Mainz, Germany, which involves completion of a prototype to collect images Caroline Smith 5 days ago ASX News Healthcare Medical Devices
PYC PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)... Jonathon Davidson 31 Jan 2025 10:47 (AEDT) ASX News Healthcare Biotechnology
BGT Bio-Gene jumps sharply as US DoD awards grants for novel insecticide development Bio-Gene Technology (ASX:BGT) has revealed its receipt of contracts from the US Department of Defence to assess BGT's insecticides. Jonathon Davidson 29 Jan 2025 11:33 (AEDT) ASX News Chemicals Healthcare Chemicals
TLX Telix clocks +150% year-on-year returns as radiopharma acquisition well received Telix Pharmaceuticals (ASX:TLX) has joined a somewhat quiet cohort of ASX biotech companies having a pretty good run lately. Jonathon Davidson 28 Jan 2025 12:33 (AEDT) ASX News Healthcare Biotechnology